We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by fengshufang, Xijing Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01370304
First Posted: June 9, 2011
Last Update Posted: February 15, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
fengshufang, Xijing Hospital
  Purpose
The purpose of this study is to treat participants with a diagnosis of depressive disorder to assess the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) and venlafaxine in the treatment of depressive disorders compared venlafaxine only (the optimal medication) and to rTMS only. fMRI will be performed to determine if treatment response is related to changes in fMRI, and use it to investigate the respondence to the treatments.

Condition Intervention Phase
Depression Other: active rTMS and active Venlafaxine Other: active rTMS and sham Venlafaxine Other: sham rTMS and active Venlafaxine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Repetitive Transcranial Magnetic Stimulation (rTMS) Compared or Associated With Venlafaxine for Depressive Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study

Resource links provided by NLM:


Further study details as provided by fengshufang, Xijing Hospital:

Primary Outcome Measures:
  • The primary outcome measure is remission [ Time Frame: 1-6 weeks ]
    It will be evaluated using the Hamilton Depression Rating Scale (HDRS-17 < 8)


Secondary Outcome Measures:
  • fMRI [ Time Frame: 0,6 weeks ]
  • CGI [ Time Frame: 1-6 weeks ]
    Using the Clinical Global Impression scale(CGI)

  • QIDS-C30 [ Time Frame: 1-6 weeks ]
  • UKU Scale [ Time Frame: 1-6 weeks ]
    Side effects will be assessed using the UKU Scale


Estimated Enrollment: 60
Study Start Date: June 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: active rTMS and active Venlafaxine Other: active rTMS and active Venlafaxine

rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks

Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks

Other Names:
  • venlafaxine: Wyeth
  • rTMS: MagVenture
Experimental: active rTMS and sham Venlafaxine Other: active rTMS and sham Venlafaxine
rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
Other Names:
  • venlafaxine: Wyeth
  • rTMS: MagVenture
Sham Comparator: sham rTMS and active Venlafaxine Other: sham rTMS and active Venlafaxine

rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region

Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks

Other Names:
  • venlafaxine: Wyeth
  • rTMS: MagVenture

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years and older
  • Clinical diagnosis of major depressive disorder (DSM-IV)
  • HDRS-17 items > 20
  • Failure of one antidepressant treatment (efficacious doses for 6 weeks at least)

Exclusion Criteria:

  • Psychotic features
  • Failure of one previous venlafaxine treatment
  • Addiction comorbidity or schizophrenia comorbidity
  • Involuntary hospitalization
  • Seizures history
  • Pregnancy or breastfeeding
  • Somatic comorbidity able to impact on cognitive functions
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01370304


Contacts
Contact: Yunchun Chen, Ph.D +086-13720582601 Yunchunchen@163.com
Contact: Shufang Feng, Ph.D +086-13227807801 fangshuan1984@yahoo.com.cn

Locations
China, Shaanxi
Yun chun Chen Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Yun chun Chen, Ph.D    +086-13720582601    Yunchunchen@163.com   
Contact: Shufang Feng, Ph.D    +086-13227807801    fangshuan1984@yahoo.com.cn   
Principal Investigator: Zhuo Wang, M.D         
Sponsors and Collaborators
Xijing Hospital
Investigators
Study Chair: Qingrong Tan, Ph.D Department of Psychiatry, Xi Jing hospital, Xi'an, China
  More Information

Responsible Party: fengshufang, Fourth Military Medical University, Department of Psychosomatics, Xijing Hospital, Xijing Hospital
ClinicalTrials.gov Identifier: NCT01370304     History of Changes
Other Study ID Numbers: 20110526-09
First Submitted: June 8, 2011
First Posted: June 9, 2011
Last Update Posted: February 15, 2012
Last Verified: February 2012

Keywords provided by fengshufang, Xijing Hospital:
repetitive Transcranial Magnetic Stimulation (rTMS)
Depression
Venlafaxine
fMRI

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Venlafaxine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs